|
Sinoway Industrial Co.Ltd.
|
Product name
|
Febuxostat
|
CAS No.
|
144060-53-7
|
Molecular Formula
|
C16H16N2O3S
|
Molecular Weight
|
316.3748
|
Quality Standard
|
99% up by HPLC, EDMF
|
Appearance
|
White powder
|
ITEMS
|
SPECIFICATIONS
|
RESULTS
|
CHARACTERISTICS
|
A WHITE OR WHITE CRYSTALLINE POWDER
|
COMPLIES
|
IDENTIFICATION
|
POSITIVE
|
COMPLIES
|
SOLUBILITY OF SOLUTION
AND COLOUR
|
COMPLIES
|
COMPLIES
|
ASSAY(BY HPLC)
|
98%~102%
|
99.7%
|
RELATED IMPURITIES
|
NMT0.1%
|
0.1%
|
LOSS ON DRYING
|
NMT0.5%
|
0.2%
|
RESIDUE ON IGNITION
|
NMT0.2%
|
0.05%
|
HEAVY METALS
|
NMT0.001%
|
NMT0.001%
|
CONCLUSION:THE PRODUCT COMPLIES WITH EDMF STANDARD.
|
Function of Febuxostat
The main effect of febuxostat is to promote uric acid excretion and inhibit uric acid production.
At present, the drugs for the treatment of elevated uric acid in my country mainly include two categories: 1. Drugs that promote the excretion of uric acid, such as benzbromarone; 2. Drugs that inhibit the production of uric acid, the most representative of which is allopurinol. Febuxostat is a new type of uric acid-lowering drug with a similar mechanism of action to allopurinol, mainly inhibiting xanthinase, thereby inhibiting the production of uric acid. At the same time, febuxostat has less side effects and has less impact on liver and kidney function, especially patients with moderate or lower renal insufficiency can use febuxostat with confidence. At the same time, patients can achieve a good therapeutic effect on gout by cooperating with diet and strict low-purine diet.
|
Send Inquiry
|
Pharma Sources Insight June 2024: Globalization on the Go
